New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTMMM, MMM, GWW, GWW, UNP, UNP, SWK, SWK, LUV, LUV, RTN, RTN, PCP, PCP, MKC, MKC, LMT, LMT, KEY, KEY, EQT, EQT, DOV, DOV, CELG, CELG, BMY, BMY, BAX, BAX, ABC, ABC, ARG, ARG, XRX, XRXCompanies reporting Before the Market Open on Thursday, January 24
Notable companies reporting before the opening bell on Thursday include 3M Co (MMM), Airgas (ARG), AmerisourceBergen (ABC), Baxter International (BAX), Bristol-Myers Squibb (BMY), Celgene (CELG), Dover (DOV), EQT (EQT), KeyCorp (KEY), Lockheed Martin (LMT), McCormick & Company (MKC), Precision Castparts (PCP), Raytheon (RTN), Southwest Airlines (LUV), Stanley Black & Decker (SWK), Union Pacific (UNP), W.W. Grainger (GWW), and Xerox (XRX).
News For MMM;ARG;ABC;BAX;BMY;CELG;DOV;EQT;KEY;LMT;MKC;PCP;RTN;LUV;SWK;UNP;GWW;XRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 25, 2015
07:00 EDTLUVDelta granted temporary space at Dallas airport by Southwest, Reuters reports
While Southwest Airlines (LUV) and Delta Air Lines (DAL) await a resolution of their dispute in court, Southwest is allowing Delta to continue operating five daily flights between Dallas Love Field Airport and Atlanta, reported Reuters, citing a Delta spokeswoman. A gate-sharing pact between the two is set to expire on July 6, the report noted. Reference Link
June 24, 2015
18:21 EDTLMTLockheed Martin awarded $480M government contract
Subscribe for More Information
10:00 EDTMKCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:29 EDTBMYFDAnews to hold a summit
Subscribe for More Information
07:04 EDTMKCMcCormick upgraded to Outperform from Market Perform at Bernstein
06:33 EDTMKCMcCormick to acquire Stubb's barbeque sauces for about $100M in cash
Subscribe for More Information
June 23, 2015
18:07 EDTBAXBaxter initiated with a Buy at Goldman
Subscribe for More Information
16:22 EDTLMTAerojet Rocketdyne awarded contract by Lockheed Martin
Aerojet Rocketdyne (AJRD) recently was awarded a contract from Lockheed Martin (LMT) to deliver XR-5 Hall Effect and MR-510 Arcjet electric propulsion subsystems, as well as monopropellant rocket engines for the modernized A2100 satellite. The contract is for delivery of the flight propulsion subsystems aboard two modernized A2100 satellites that Arabsat recently ordered from Lockheed Martin.
09:03 EDTMMM3M to buy Capital Safety from KKR in deal valued at $2.5B
3M (MMM) announced it has entered into a definitive agreement to acquire Capital Safety from KKR (KKR) for a total enterprise value of $2.5B, including the assumption of approximately $700M of debt, net of cash acquired. The business employs approximately 1,500 people worldwide and is headquartered in Bloomington, Minnesota. On a GAAP reported basis, 3M estimates the acquisition to be 4c dilutive to earnings in the first 12 months following completion of the transaction. Excluding purchase accounting adjustments and anticipated one-time expenses related to the transaction and integration, 3M estimates the acquisition to be 12c accretive to earnings over the same period. The transaction is expected to close in the third quarter, subject to customary closing conditions and regulatory approvals. 3M will finance the transaction with existing cash, a portion of which will come from outside the U.S.
07:12 EDTLUVSouthwest coverage assumed with an Underweight at Morgan Stanley
Subscribe for More Information
June 22, 2015
17:21 EDTLMTLockheed Martin awarded maximum $870M government contract modification
Subscribe for More Information
14:31 EDTMMM3M files patent infringement suit in Korea against LMS Co. Ltd.
3M Innovative Properties Co. and 3M Korea Ltd. filed a patent infringement lawsuit on June 19 in the Seoul Central District Court against LMS Co. Ltd. The suit alleges that certain LMS Co. Ltd. light management film package products, including a light management film package product sold under the product name of “XLAS,” infringe 3M’s Korean Patent No. 1,074,570 titled "Method for Stacking Surface Structured Optical Films." 3M’s microreplicated stacked prism films, including 3M Advanced Structured Optical Composites (ASOC), are integrated into LCD displays. The prism films direct light to enable a thinner and more energy-efficient electronic display.
10:00 EDTEQTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Akebia (AKBA) initiated with an Outperform at JMP Securities... Barracuda Networks (CUDA) initiated with a Buy at Summit Research... BioLineRx (BLRX) initiated with an Outperform at JMP Securities... Cabela's (CAB) initiated with an Outperform at Barrington... Chemours (CC) initiated with a Buy at Jefferies... Communications Sales & Leasing (CSAL) initiated with an Overweight at JPMorgan... E.W. Scripps (SSP) initiated with a Hold at Evercore ISI... EQT Corporation (EQT) reinstated with an Overweight at Barclays... EQT GP (EQGP) initiated with an Outperform at Credit Suisse... EQT Midstream Partners (EQM) initiated with a Buy at Deutsche Bank... Eagle Pharmaceuticals (EGRX) initiated with an Outperform at RBC Capital... Energen (EGN) initiated with a Buy at KLR Group... Ignyta (RXDX) initiated with an Overweight at Piper Jaffray... International Game (IGT) initiated with a Buy at BofA/Merrill... Leju (LEJU) initiated with an Overweight at Barclays... Micron (MU) initiated with an Outperform at Cowen... People's Utah Bancorp (PUB) initiated with a Buy at DA Davidson... SouFun (SFUN) initiated with an Overweight at Barclays... Turquoise Hill (TRQ) initiated with an Outperform at BMO Capital.
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:49 EDTXRXXerox error-rate reduction not reflected in Street estimates, says Susquehanna
Subscribe for More Information
07:19 EDTLUVAirlines focusing on upgraded in-flight web services, WSJ reports
Subscribe for More Information
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
05:35 EDTEQTEQT Corporation reinstated with an Overweight at Barclays
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitman’s lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children’s Hospital, Professor Whitman’s lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvard’s Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitman’s lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
June 21, 2015
13:03 EDTLUVU.S. airline stocks may rise 15%-50% in one year, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use